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Thehepatic portal vein transportsnutrients fromthegastrointestinal
tract to the liver and ensures that xenobiotics present in food are
processed in the liver before they reach the entire circulatory system.
Thus, the liver is the major organ for coordinating the circulation of
energy-providing metabolic substrates and the disposal of toxic
products. In the liver,members of thenuclear receptor (NR) superfamily
of transcription factors can sense ﬂuctuating levels of small lipophilic
molecules that reﬂect the body's metabolic status; as a result, NRs
promptly adapt the energy homeostasis of the body to environmental
changes by modulating the transcription of genes involved in a broad
range of metabolic response programs. Female and male livers show
considerable sexual dimorphism in gene expression [1], most likely due
to differences in themetabolic needs for reproduction. Notably, a recent
proteomic study revealed that the expressionof liver proteins is affected
more by gender than by nutritional status [2]. Despite 25 years of
intensive studies onNRs, the research in thisﬁeld hasmainly focused on
one sex, primarily males; moreover, in some studies, the sex of the
subjects was not even mentioned.
In this review, ﬁrst, we summarize the current knowledge on
hepatic, sex-associated roles of individual NRs. Second, we show thatsexual dimorphism affects both the level of individual gene expression
and the concerted activities of interconnected genes controlled by
NRs. Finally, we discuss the hypothesis that this sex-dimorphic NR
“interactome” targets selected pathways in the liver, and deregulation
of these pathways may favor the development of sex-biased diseases.
2. Sexual dimorphism in nuclear receptor expression
In the liver, growth hormone (GH) regulates the expression of
different genes. GH is synthesized in the CNS pituitary glands. Its
secretion from the pituitary is subject to testosterone exposure, which
imprints pulsatile GH signaling inmales from neonatal life to adulthood
[3]; in contrast, pituitary secretion of GH is nearly continuous in females
[4]. This is a major factor in establishing and maintaining sexual
dimorphism in hepatic gene transcription. This dimorphism has been
observedboth in the secretionofGHand in theexpressionof its receptor
(GHR). For instance, transcription of a liver-speciﬁcGHR (ghr1) is higher
in females than in male rats [5]. 17β-Estradiol (E2), by increasing or
feminizing the GH levels [6], may indirectly affect GHR expression: in
fact, E2 treatment induced ghr1 inmale rats; conversely, an ovariectomy
or treatmentwith the antiestrogen, tamoxifen, reduced ghr1 expression
in females [5]. Thus, sexual dimorphism in GH expression is controlled
by testosterone, and sexual dimorphism in the GHR appears to be
indirectly controlled by estrogen. This sets up a sex-dimorphic
hormonal axis, with species-speciﬁc characteristics. For instance, the
GH secretion pattern is particularlymarked in rats [7], wherefore a lot of
the information regarding sex differences comes from these animals.
Another rodent, the mouse, has a less pronounced sex-dependent
GH secretion pattern [8] and the human even less [9], despite sex
differences in hepatic geneexpression are evident also formice [10]. The
GH axis elicits several intracellular signaling pathways, including
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transducer and activators of transcription), which are largely respon-
sible for the sex-dimorphic gene expression in the male liver [11].
Although Stat5b is a major player, it is not by itself responsible for all
the observed sex differences in hepatic gene expression. Furthermore,
the mechanisms of female predominant hepatic gene expression are so
far less clear. Interestingly, some GH-responsive transcription factors
enriched in female liver have been recently described [12].
The surgical disruption of the GH axis (e.g., with a hypophysec-
tomy) caused impaired hepatic expression of some nuclear receptors
in rats, including the estrogen receptor alpha (ERα, NR3A1) [13] and
the glucocorticoid receptor (GR, NR3C1) [14]; this suggested potential
GH-dependent sex-dimorphic expression of these receptors. In
mice, the inﬂuence of pituitary hormones on liver gene expression
was recently investigated in both sexes by microarray analysis
following hypophysectomy [15]; 10 pituitary-responsive nuclear
receptors were found in this dataset (Fig. 1). However, only three
receptor genes (namely, errα (NR3B1), errγ (NR3B3), and rxrγ
(NR2B3)) showed differential response to hypophysectomy in the
two sexes, suggesting that, if the pituitary hormones play a regulatory
role in NR expression, other factors might determinate their sex-
dimorphic expression. Those results gave rise to the question of
whether the expression of NRs is really different in male and female
livers. We found that this was indeed the case with a simple cross-
sectional proﬁling of NR expression in livers of male and female mice
[16]; 17 of the 38 NRs expressed in the liver were sex-dimorphic
(Fig. 1). For instance, rarγ (NR1B3), errβ (NR3B2), and trβ (NR1A2)mRNA (log2 M/F)
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Fig. 1. Sexual dimorphism in nuclear receptor expression and function. This microarray-de
study [16]. Sex differences are expressed as the log2 of the ratio between the absolute signal
color is proportional to the prevalence of expression in females (pink) or males (blue). The
negative response: arrow down) was observed in a gene expression study on the effect of hy
indicated (green dots). The text in the right column indicates the appropriate section in whwere predominantly expressed in male liver, and errγ, rxrγ, and pparγ
(NR1C3)were predominantly expressed in female liver. Interestingly,
for most hepatic sex-dimorphic NR functions, which are discussed
in the following sections, we found no evidence of differential gene
expression in ourmicroarray analysis (Fig. 1 and Section 3). This led to
two non-mutually exclusive conclusions; ﬁrst, the data in Fig. 1 may
underestimate the global NR sex dimorphism, because it did not take
into account the effects that circadian rhythms, fasting-to-feeding
transitions, or estrous cycles might have on NR expression; second,
sex-dimorphic NR functions might be governed by mechanisms other
than mRNA expression levels (i.e., post-translational modiﬁcations).
For instance, we previously found that a fraction of the hepatic
peroxisome proliferator-activated receptor-α (PPARα, NR1C1) pro-
tein was sumoylated preferentially in females [16]. Structural
modeling of the PPARα ligand-binding domain (LBD) revealed that
the agonist-induced change in the LBD conformation caused the
sumoylation-targeted Lys358 residue to move to the surface of the
molecule, making it available for this modiﬁcation. In fact, sumoyla-
tion of the PPARα LBD triggered the interaction between PPARα and
the LXXLL peptide motif of the GA binding protein-alpha (GABPα),
which was bound to the steroid oxysterol 7α-hydroxylase cyto-
chrome P450 7b1 (cyp7b1) promoter used in the model. Furthermore,
despite the “agonist-like” conformation required for sumoylation,
the thus-modiﬁed PPARα recruits the NR corepressor (NCoR [16,17]).
DNA and histone methyltransferases are also recruited, and these
methylate a Sp1-binding site near the GABP sites and histones. These
events resulted in the loss of Sp1-stimulated expression and, thus, the8
Pituitary
response Sex-dimorphic NR functionsM F
 
rived data show nuclear receptor mRNA expression levels in the liver from a previous
s obtained in male vs. female livers harvested 2 h after dark (ZT14). The intensity of the
impact of pituitary hormones on NR expression in liver (positive response: arrow up,
pophysectomy in both sexes [15]. Known sex-dimorphic nuclear receptor functions are
ich they are discussed.
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sumoylation induces a switch in PPARα activity: when sumoylated,
PPARα can function as a repressor of speciﬁc promoters. Furthermore,
the observation that sumoylated PPARα is more abundant in females
compared to males suggested that post-translational modiﬁcations
are anothermeans of effectively invoking sex-dimorphic NR signaling.
3. Sexual dimorphism in nuclear receptor function
In this section, for each NR class (steroid receptors, RXR hetero-
dimers, orphan receptors), we discuss in detail the known sex-
dimorphic functions summarized in Fig. 1; we do not address other
roles for these receptors. Understanding their sexual dimorphism will
contribute to gaining better insight into the multitude of functions
carried out by the liver.
3.1. Sexual dimorphism in classic steroid receptors
3.1.1. Estrogen receptors
Estradiol binds and activates two NR isotypes, the estrogen
receptor alpha (ERα, NR3A1 [18]) and the estrogen receptor beta
(ERβ, NR3A2). Hepatocytes mainly express ERα, and cholangiocytes
[19] and stellate cells [20] express ERβ. To date, we have information
related to liver sex dimorphism for ERα, which converges on a
putative anti-inﬂammatory pathway in the female liver. Inﬂammation
is a nonspeciﬁc immune response to infection, irritation, and injury.
Gender differences in the severity of inﬂammatory diseases (e.g.,
atherosclerosis, neurological disorders, periodontitis, and rheumatoid
arthritis) suggest that female sex hormones modulate the inﬂamma-
tory response [21]. The liver-produced acute phase response proteins
are biomarkers of inﬂammation, infection, and trauma. A recent
observation illustrated the protective role of ER in liver: all female
mice and male mice treated with E2 survived liver ischemia and
reperfusion injury; in contrast, all ERα-null males and 60% of ERα-null
females died within 3–5 days after the injury [22]. Similarly, studies in
human and animal models have demonstrated that females in the
proestrus phase (i.e., with high estrogen levels) tolerated trauma-
hemorrhage and sepsis far better than males [23]. This protection
seems due, at least in part, to the ability of E2-activated ER to enhance
heme-oxygenase 1 (HO-1)-mediated downregulation of the inﬂam-
matory response [24]. Furthermore, E2 administration following a
trauma-hemorrhage also contributed to reducing liver injury by
decreasing neutrophil accumulation and reducing Kupffer cell
production of the cytokine-induced neutrophil chemoattractant-1
(CINC-1 [25]). In mice exposed to diethylnitrosamine, estrogen
inhibited the secretion of interleukin 6 from liver macrophages; this
decreased both inﬂammation and carcinogenesis [26]. Similarly, in
response to systemic inﬂammation induced by endotoxin, female mice
and males pretreated with E2 produced less tumor necrosis factor-α
(TNFα) and macrophage inﬂammatory protein-1α than untreated
male mice; this conferred resistance to endotoxin-induced mortality
[27]. However, depending on the context, estrogen can assume a pro-
inﬂammatory role. Induction of sepsis with Streptococcus pyogenes
resulted in increased inﬂammation (TNFα) and mortality in females
compared to male mice, while pretreatment of females with the
ER antagonist, tamoxifen, reduced the inﬂammatory response and
mortality [28]. Thus, estrogen has a complex role in the inﬂammatory
processes, and it remains unclear how estrogen is able to modulate
inﬂammation in both directions [29], and why evolution selected
this peculiarity in females. However, it is known that, in women of
reproductive age, inﬂammatory disorders can cause gynecologic
diseases; conversely, components of the immune response are required
for optimal fertility [30].
In the liver, the role of the ER goes beyond its implication in
inﬂammation. Studies of null mice deﬁcient for ERs (ERKO) or
endogenous estrogen synthesis (ARKO) revealed a protective role ofestrogen in maintaining glucose homeostasis and insulin sensitivity
[31,32]. The absence of ERα, but not ERβ, resulted in a profound
hepatic insulin resistance in both female and male mice. Gene
expression proﬁling in the liver of ERα-null female mice also revealed
upregulation of lipogenic genes and downregulation of genes involved
in lipid transport [33]. It is not clear if these effects are female-speciﬁc.
In fact, also in male livers, the ER can be activated by exposure to
dietary phyto-estrogens [34]. More importantly, estrogen is produced
in males by aromatization of testosterone and male but not female
mice in which the aromatase gene has been deleted (ARKO) develop
hepatic steatosis that can be normalized by estrogen treatment [35].
We will further discuss ER sex-dimorphic actions on lipid/cholesterol
metabolism in Section 4.1, and on cytochrome P450 expression in
Section 4.2.
3.1.2. Androgen receptor
Androgen receptor (AR, NR3C4) gene expression is sexually di-
morphic and temporally patterned in rodent liver. This translates into
sex- and age-dependent changes in androgen sensitivity [36]. In the
male liver, AR regulates the expression of a number of proteins
important for energy homeostasis. In fact, male but not female mice
lacking the AR in liver developed hepatic steatosis (see Section 4.3)
and insulin resistance when fed a high-fat diet [37]. Furthermore,
constitutive liver-speciﬁc overexpression of the AR in female mice
downregulated the expression of the androgen-repressible enzyme,
dehydroepiandrosterone sulfotransferase (DST), which is normally
expressed at much higher levels in female compared to male liver
[36]. Interestingly, the androgenic status may inﬂuence liver suscep-
tibility to infections in a sex-dependent manner. For example, when a
recombinant, adeno-associated, viral vector (AAV) was transduced
into mice, male liver showed 5- to 13-fold higher expression
compared to females. Castration dramatically reduced the transduc-
tion efﬁciency in males, and dihydrotestosterone treatment increased
the efﬁciency in females. This suggested that high levels of AR
might have enhanced AAV hepatic tropism [38]. In addition to virus
transduction, gender dimorphism has been reported in protozoan
infections. Androgen steroids, like dehydroepiandrosterone (DHEA),
act directly upon Entamoeba histolytica growth and viability [39]. This
is consistent with the observation that human and mice females were
more resistant than males to amoebic liver abscess, due to increased
early interferon-γ (IFNγ) production in response to infection [40].
Thus, the female liver appears to be generally more resistant to
infections than the male liver. The ability of the liver to cope with
infections has a potential prognostic value in cancer development (see
Section 4.4). For instance, AR promotes hepatitis B virus-induced
hepatocarcinogenesis by enhancing viral replication [41].
3.1.3. Glucocorticoid receptor
During fasting or exercise, blood glucocorticoids (mainly cortisol in
humans and corticosterone in rodents) are increased, which activate
the hepatic GR (NR3C1). GR then mobilizes glucose to serve as an
energy source to other organs [42]. Consistent with this key function,
young mice with GR-null hepatocytes exhibited a severe growth
deﬁcit, and this deﬁcit became more pronounced in adult males
compared to females. This phenotypemost likely arose from the lack of
an interaction between GR and the sex-dimorphic transcription factor
Stat5. Consequently, this abolished the Stat5-dependent expression of
genes that promote postnatal growth [43]. In adult liver, glucocorti-
coids are inactivated by 11,β-hydroxysteroid dehydrogenase (11β-
HSD). Males have higher 11β-HSD levels than females, and 11β-HSD
expression is under the control of GH [44] and testosterone [45].
Furthermore, heat shock proteins can bind to hepatic GR, which
prevents GR from binding DNA. In rats treated with antidepressants,
heat shockprotein-GRbindingwas decreased in females and increased
in males [46]. Overall, these studies have given rise to the hypothesis
of a male-speciﬁc GR inactivation pathway, which could be a
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a characteristic of excess glucocorticoids. Accordingly, hepatic GR
deﬁciency improved liver steatosis in db/db mice [47].
3.2. Sexual dimorphism in RXR and its partner receptors
3.2.1. Retinoid X receptors
The three retinoid X receptors (RXRα or NR2B1, RXRβ or NR2B2,
and RXRγ or NR2B3) are obligate heterodimer partners for several
nuclear receptors expressed in the liver. Male hepatocyte RXRα-null
mice had reduced expression of the cytochromes cyp4a, cyp3a, and
cyp2b compared to their wild-type counterparts; in contrast, females
with or without hepatic RXR expression showed no difference in
cytochrome expression. Castration rescued gene repression in males;
this suggested that retinoid signaling counteracts some repressive
activities of the AR by amechanism that remains to be elucidated [48].
Interestingly, testosterone treatment reduced the expression of these
cyp genes only in GR-null females, but not in wild-type females [48];
this suggested a potential cross-talk between RXR, GR, and AR in
female liver.
3.2.2. Peroxisome proliferator-activated receptors
Among the three PPAR isotypes, PPARα (NR1C1) is most highly
expressed in the liver, and it has sex-dimorphic functions. In the liver,
PPARα promotes fatty acid oxidation, and it is the target of the ﬁbrate
class of hypolipidemic drugs, including fenoﬁbrate, cloﬁbrate, and
gemﬁbrozil, which are used for treating hypertriglyceridemia.
The role of PPARα in hepatic fatty acid metabolism is especially
prominent during fasting. In fasted PPARα-null mice, its absence was
associated with pronounced hepatic steatosis, decreased levels of
plasma glucose and ketone bodies, elevated plasma free fatty acid
levels, and hypothermia [49,50]. These severe metabolic disturbances
resulted from the decreased expression of a large number of genes
involved in hepatic lipid metabolism; many of these genes are direct
targets of PPARα [51]. In addition, PPARα is a target of hypothalamic
hormone signaling; furthermore, it plays an important role in the
anti-inﬂammatory action of glucocorticoids [52]. PPARα mRNA and
protein are expressed at higher levels in the livers of male rats than
in female rats. After 20 h of food deprivation, PPARαmRNA increased
by 72% in males and 52% in females. A hypophysectomy eliminated
these gender differences; this suggested that pituitary-dependent
hormones have an inhibitory effect on PPARα expression, and this
effect is more pronounced in female compared to male rats [53]. In
line with these observations, peroxisome proliferator response
element (PPRE)-dependent promoter activity, measured in transgenic
PPRE-luciferase reporter mice, was increased in males compared
to females. In the liver, luciferase activity was increased after only
6 h of fasting. Female luciferase expression was not affected by
an ovariectomy, nor by testosterone treatment; furthermore, male
luciferase expression was not decreased with an orchiectomy. In that
assay, onlymales responded to the PPARα agonistWy14,643 [54]; this
suggested that PPARα is less active in females. Those ﬁndings were
consistent with the ﬁnding that, compared to males, females showed
reduced responsiveness to some peroxisome proliferators, like
fenoﬁbrate [55], gemﬁbrozil [56], and trichloroethylene [57], and
to an aqueous extract of the Salacia oblonga [58]. However, the
conclusion that PPARα is nearly inactive in females contradicts years of
efﬁcacious ﬁbrate treatments in both women and men. In fact, the
hepatic expression of some key genes involved in the synthesis of
lipids, including ACC, FAS, and SREBP1C, was higher in female mice
compared to male mice. This difference was PPARα-dependent,
because PPARα-null female mice showed expression levels similar
to those measured in PPARα-null males [59]. This raises the question
of why females are more resistant to peroxisome proliferation.
Interestingly, treatment with WY 14,643 or gemﬁbrozil caused liver
NADPH-cytochrome P450 reductase (POR) expression to increase infemales and decrease in males [60]. POR is the obligate electron donor
for all the P450 cytochromes. Thus, the female-speciﬁc increase of
POR suggested that the ability of females to escape peroxisome
proliferation could be due to a highly efﬁcient detoxiﬁcation pathway
(see Section 4.2). Along these lines, male, but not female, rats
developed more steatosis in response to a high-fat diet [61]. This
supports the idea that the female liver performs better than the male
liver against lipid oxidative stress. To measure the extent of sexual
dimorphism in PPARα-mediated gene regulation in the liver, we
performed a microarray study that compared the mRNA expression
proﬁles of male and female mice in the presence or absence of
PPARα. The experiment was performed with RNA from hepatic
tissues harvested at 2 h after dark, when PPARα-stimulated genes are
expected to reach maximum expression [16]. Our results showed
that, in the liver, PPARα stimulated a similar number of genes in both
sexes (66 genes in females vs. 60 genes in males). However, only half
of these genes (32 genes) were commonly upregulated in both sexes;
this conﬁrmed a clear sex dimorphism that was also observed in
the number of genes downregulated by PPARα (50 in females vs.
24 in males) [62]. This analysis highlighted the possible pitfalls of
generalizations based on studies that only included animals of one
sex to determine the functions of NRs. Because NR actions are in part
sex-biased, it makes sense that sexual differences would be less
apparent when NR action is compromised. However, this does not
always hold true, probably due to the subtle regulation of NR action.
For instance, ablation of PPARα did not alleviate sexual dimorphism.
PPARα-null females were hyperphagic compared to males and, upon
fasting, their circulating leptin levels increased twice as much as the
increase observed in null males. This led to an exaggerated leptin
response to refeeding [63]. This effect was abolished with a highly
pulsatile (intermittent) GH treatment that corresponded to the GH
secretionpattern ofmale animals [63]. Consistentwith this phenotype,
a long-term aging experiment showed that serum triglycerides
were higher in PPARα-null, aged females compared to aged males,
and the females developed more pronounced obesity than males
[64]. Sex-dimorphic steatosis was also observed in this model (see
Section 4.3).
3.2.3. Liver X receptors
The liver X receptors, LXRα (NR1H2)and LXRβ (NR1H3), are key
regulators of transcriptional programs involved in lipid homeostasis
and inﬂammation [65]. When double-knockout LXRαβ−/− mice
were challenged with a high-fat diet, one study conducted in males
[66] and one conducted in females [67] pointed to similar resistance in
diet-induced obesity. However, the activation of LXRα increased
urinary bile acid elimination in females, which appeared to confer a
female-speciﬁc resistance to lithocholic acid-induced hepatotoxicity
and bile duct ligation-induced cholestasis. These effects were not
appreciable in males [68]. The relevance of this sex-dimorphic pro-
tection is not fully understood, but it may be beneﬁcial in attenuating
estrogen-induced intrahepatic cholestasis.
3.2.4. Thyroid hormone receptors
Thyroid hormone impacts diverse metabolic pathways important
in glucose and lipid metabolism, lipolysis, and regulation of body
weight [69]. For instance, overt hypothyroidism causes hypercholes-
terolemia and LDL accumulation in the liver; this can be normalized
with thyroxine treatment. Consumption of a soy protein isolate
increased the thyroid hormone receptor-beta-1 protein (TRβ1,
NR1A2) content in both male and female rat livers, but the increase
in females was much higher than that in males. Interestingly, the
binding of TR to the promoter of TR-target genes was signiﬁcantly
inhibited by increasing the amount of soy proteins in the diet of
female rats. The greater effects of soy protein in female than in male
rats suggested that their action was potentiated by female sex
steroids; however, this remains to be demonstrated [70].
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The pregnane X receptor (PXR, NR1I2) and the constitutive
androstane receptor (CAR, NR1I3) are closely related and liver-
enriched. They were ﬁrst deﬁned as xenobiotic receptors. PXR
and CAR regulate the transcription of genes that encode drug-
metabolizing enzymes (several cytochrome P450s, sulfotransferases,
UDP-glucuronosyltransferases, and glutathione transferases) and
transporters, which prevent the accumulation of harmful chemicals
in the liver. PXR and CAR also have an endobiotic function in the
regulation of glucose and lipid metabolism. Conversely, deregulation
of glucose and lipid metabolism in obesity and diabetes has a major
impact on drug metabolism [71]. CAR is also important for sex
differences in the expression of cyp2b genes, which are more highly
expressed andmore active in females than inmales [72]. Males appear
to be less sensitive than females to both indirect and moderated
CAR activators; for example, nonylphenol (NP) induces the CAR target
genes cyp2b10, cyp2c29, and cyp3a11 only in females [73]. The
transcriptional activity of CAR in males appears to be partially
counteracted by relatively high physiological levels of androgen. For
instance, the potent CAR ligand TCPOBOP, caused marked prolifera-
tion of hepatocytes in female, but less in male mice [74]. Activation of
PXR by pregnenolone-16α-carbonitrile (PCN) induced the female-
speciﬁc cyp3a44 mRNA in male mice, but no induction was detected
in female mice [75]. Collectively, these observations have led to the
speculation that the activation of xenobiotic receptors is more
prominent in females than males. However, in PXR-CAR double-null
mice, a regimen of lithocholic acid causedmarked cholestasis in males
but not in females; moreover, it was associated with the suppression
of bile acid transporters in male livers [76]. Those results revealed a
complex balance between these two NRs in both sexes. This balance
might be ﬁne-tuned by the differential action of other NRs, like PPARs
or GR. For instance, PPARα ligands induced CAR nuclear translocation
in mouse hepatocytes in vivo [77]. Furthermore, sex differences
have been postulated for the porphyrogenic acute attack through
GR-mediated effects on CAR/PXR; CAR/PXR can activate the gene
encoding 5-aminolevulinate synthase, a gate-keeping enzyme that
regulates the precursors of the porphyrogenic acute attack [78].
3.3. Sexual dimorphism in classic orphan receptors
To date, sexual dimorphism has not been reported for orphan
receptors, with the notable exception of the hepatocyte nuclear factor
4-α (HNF4α, NR2A1). In a liver-speciﬁc, HNF4α-null mouse model,
about 1000 fewer genes were affected by the loss of HNF4α in female
liver compared to male liver; this indicated sexual dimorphism in
HNF4α regulation of gene expression [79]. Thus, HNFα appears to be
the primary mediator for the dimorphic expression of Cyp P450s [80].
4. Convergence of sex-dimorphic NR actions on target pathways
and liver diseases
As indicated in the previous section, the current knowledge of sex-
dimorphic NR actions converges mainly on two common hepatic
pathways: cholesterol metabolism and detoxiﬁcation (i.e., differential
expression of cytochromes P450).
4.1. Cholesterol metabolism
Like other steroids produced from cholesterol, the physiological
estrogen hormone (17β-estradiol, E2) induces sexually differential
effects on cholesterol metabolism in the liver. In adult rats, the rate-
limiting enzyme in cholesterol synthesis, HMG-CoA reductase, showed
lower activity and expression in females and E2-treated males than
in untreated males [81]. Thus, ER activity could explain some of the
sexual dimorphism in hepatic regulation of cholesterol homeostasis.
However, in liver biopsies from male patients undergoing estrogentreatment for prostate cancer, the enzymatic activity of HMG-CoA
was increased [82]. Similarly, overexpression of ERα in mouse liver
increased cholesterogenesis and led to biliary hyper-secretion of
cholesterol [83]. In Section 3.2.2, we mentioned that PPARα represses
different genes of the cholesterol pathway and that it could counteract
estrogenic actions on biliary secretion [16]. Taken together, these
results indicate that, as in inﬂammation (Section 3.1.1), ER appears to
inﬂuence cholesterol metabolism in both directions, depending on the
experimental/clinical setting [84]. In addition, synthetic molecules
designed to modulate ER action elicited sex-dimorphic responses.
For instance, Alcobifene, a selective ER modulator, decreased liver
cholesterol and triglyceride concentrations only in femalemice through
the direct activation of ERα [85]. Not only the synthesis of cholesterol
but also the elimination of cholesterol is gender-dimorphic. Female liver
expresses the akr1b7 gene, which encodes an aldo-keto reductase
involved in the detoxiﬁcation of isocaproaldehyde, a product of
cholesterol catabolism, and 4-hydroxynonenal, which is formed by
lipid peroxidation. The female-enhanced expression of akr1b7 is
regulated by the secretion pattern of GH, and it can be repressed by
treatment with dexamethasone (ligand for GR) and T1317 (ligand
for LXR and PXR) [86]. This example supported our hypothesis that
the NR crosstalk between LXR, PXR, and GR is potentiated in female
liver. Most enzymes operating in the cholesterol pathway are oxido-
reductases (i.e., cytochromes P450s). The expression of the P450 family
of cytochromes in liver is markedly sex-dimorphic [87], with different
members of this family being involved in detoxiﬁcation processes.
4.2. Detoxiﬁcation
The liver plays a key role in the elimination of unwanted toxic
substances. It removes a broad spectrum of endotoxins carried from
the intestine to the liver by the portal vein; thus, the hepatic
reticuloendothelial system serves as a blood cleanser [88]. This process
may also be sex-dimorphic. The female hormone 17β-estradiol
increases sensitivity of hepatic Kupffer cells to endotoxin in rats [89],
while AR increases the odds for hepatic infection. This raises the
possibility that the female liver is more efﬁcient in neutralizing
substances carried by the portal vein. In fact, themetabolic activities of
the liver produce hydrophobic toxic molecules that are eliminated in
the hepatocyte through the detoxiﬁcation pathway. This pathway
proceeds through a complex series of chemical reactions that convert
lipophiles into more water-soluble metabolites, which are efﬁciently
excreted in the urine. This protective mechanism stems from the
expression of a wide variety of xenobiotic biotransforming enzymes.
These enzymes catalyze the oxidation, reduction, and hydrolysis
(Phase I enzymes) and/or conjugation (Phase II enzymes) of functional
groups on drugs and other xenobiotics. Because the physiological
requirements for steroid hydroxylation differ between the sexes,
many members of the cytochrome P450 superfamily are expressed in
the liver in unique, sex-dependent patterns [87]. The major classes of
cyp genes are selectively controlled by certain ligand-activated NRs;
thus, they form tightly controlled networks [90]. In fact, several NRs
modulate sex-dimorphic cytochrome P450 expression. For instance, in
the liver of ERα-null female mice, the “male” transcription factor
Stat5b was localized in the nuclei of hepatocytes, which resulted in
repression of the female-speciﬁc cyp2a4 (steroid 15α-hydroxylase)
and stimulation of themale speciﬁc cyp2d9 (steroid 16α-hydroxylase)
hepatic genes [91]. PPARα contributes to the maintenance of basal
cyp4a11 expression in transgenic mice carrying the human cyp4a11.
For example, basal levels of cyp4a11 were reduced differentially in
PPARα-null females (N95%) andmales (b50%) compared to wild-type
mice [92]. In a second example, hepatic cyp4a12 expressionwasmale-
speciﬁc in wild-type, but not in PPARα-null mice [93]. The known
roles of NRs in determining sexual dimorphism in cyp expression are
shown in Fig. 2. Interestingly, different NRs appear to have different
speciﬁcities in inﬂuencing liver dimorphism. For instance, some
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including Cyp2, Cyp3, and Cyp4. Furthermore, single cytochromes are
modulated by more than one receptor. For example, cyp2b10 exhibits
sex-dimorphic regulation by HNF4-α, RXRα, and CAR. Thus, the sexual
dimorphism of cytochrome P450 appears to be regulated by a
hierarchical network of different NR activities. This hierarchical
control of dimorphism appears to be recursive, because the xenobiotic
detoxiﬁcation pathwaymay result in the production of ligands for NRs,
which are also differentially produced in the sexes. For instance, the
catabolism of a 2,4-thiazolidinedione insulin sensitizer generates a
potent PPARγ activator in the liver of female rats, dogs, and monkeys,
but not in male animals [94]. In conclusion, the response to drug
exposure is notably sex-dimorphic; this fact puts into question the
gender-biased trend in drug discovery [95] and clinical trials [96]. In
other words, when evaluation of the clinical efﬁcacy and toxicity of a
drug is only performed in men or women, it remains incompletely
tested for half of the population. According to a recent prospective
study, acute liver failure due to drug-induced liver injury is prominent
inwomen (70% of patients [97]). This raises the embarrassing question
of whether we are preferentially selecting drugs that are safer for the
male population than for the female population.
4.3. Unbalanced lipid metabolism: steatosis
Not only an improper xenobiotic catabolism but also an impaired
metabolism of nutrients like dietary lipids can predispose the liver to
disease in a sex-dimorphic way. Steatosis is a hallmark of different
hepatic diseases. Steatotic liver is characterized by an abnormal
retention of lipids in the hepatocytes, which reﬂects impairment in the
equilibrium of two opposing pathways: lipid input and lipid output.
Lipid input is from triglycerides derived from dietary chylomicronsCyp2A4 Wiwi 2004
Cyp2B10 Wiwi 2004 Cai 2003 Hernandez 
Cyp2B13 Wiwi 2004
Cyp2B9 Wiwi 2004
Cyp2C12 Wiwi 2004
Cyp2C29 Hernandez 
Cyp2D9 Wiwi 2004
Cyp3A11 Cai 2003 Hernandez 
Cyp3A41 Wiwi 2004
Cyp3A44 Wiwi 2004 Anakk 20
Cyp4A1 Cai 2003
Cyp4A11
Cyp4A12 Wiwi 2004
Cyp7B1
upregulation prevalent in male
Fig. 2. Sexual dimorphism in nuclear receptor-mediated expression of cytochrome P450 enzy
in a sexually dimorphic way are indicated (pink: regulated in females, blue: regulated in mor de novo synthesized in the liver; lipid output is from VLDL secretion
or fatty acid catabolism by β-oxidation. Lipid metabolism is clearly
gender-dimorphic [98], and this is expected to be reﬂected in the
prevalence of steatosis. In fact, nonalcoholic fatty liver disease
(NAFLD) appears to be more prevalent in men than women [99].
Because some NRs (i.e., PPARs) regulate the expression of genes
involved in lipid metabolism, their genetic deletion affects lipid
homeostasis and, consequently, hepatic steatosis. In PPARα-null mice,
gross hepatic abnormalities, revealed by the pale color of the steatotic
liver and hepatomegaly, were found in males, but not females [64].
The basis for increased resistance to steatosis in female PPARα-null
mice appeared to be due to a higher capacity to secrete triglycerides
in VLDL compared to male mice [100]. These results suggested that
PPARαmust be more essential in male liver, compared to female liver,
for preventing steatosis. Interestingly, when the hepatic functions
of other NRs were perturbed, the same phenotype was observed.
For instance, male mice that expressed a mutated form of TRα
(P398H) developed hepatic steatosis; this was probably due to direct
competition with PPARα on PPRE-containing promoter regions [101].
Similarly, liver-speciﬁc AR-knockout mice developed hepatic steatosis
and insulin resistance under a high-fat diet, but only in males [37].
Furthermore, aromatase-null mice had inactivated ERs due to the
impaired synthesis of 17β-estradiol, but only the males had elevated
hepatic triglyceride levels, which led to hepatic steatosis. Estrogen
replacement reversed this phenotype [35]. Estrogen signaling also
appeared to be important in PPARα-null mice. In this model, the
steatotic phenotype was exacerbated by treatment with etomoxir,
which abolishes lipid oxidation by inhibiting long-chain fatty acid
transport into the mitochondria. This resulted in 100% mortality for
males, but only 25% for females. However, when the male PPARα-null
mice were pretreatedwith 17β-estradiol, etomoxir-inducedmortalitySueyoshi 1999
2009
2009
Sueyoshi 1999
2009
Sakuma 2008
07 Sakuma 2008
Savas 2009
Jeffery 2004
Leuenberger 2009
upregulation prevalent in female
downregulation prevalent in female
mes. For each cytochrome listed, the nuclear receptors known to regulate its expression
ales). Citations to the relevant bibliographic references are given in the colored boxes.
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female component markedly promotes lipid homeostasis, which
tips the balance of the NR interactome toward improved steatogenic
states. In line with this proposition, tamoxifen, a potent estrogen
receptor antagonist, caused severe forms of steatosis that progressed
towards nonalcoholic steatohepatitis [103]. In the steatotic liver,
the excess of free fatty acids inside the cells is thought to trigger the
production of reactive oxygen species, thereby causing lipotoxicity
and inﬂammation [104].
4.4. Liver inﬂammation
Several nuclear receptors including ER, PPARα, FXR, PXR, CAR,
SHP, HNF4α, and VDR modulate hepatic inﬂammation (for a review,
see Ref. [105]). However, whether all of them have sex-dimorphic
functions in this context is less clear. There is a vast array of literature
illustrating the protective role of estrogen in the liver (for a review,
see Ref. [106]). As previously discussed, ER has the potential to
modulate hepatic inﬂammation in a sex-dimorphic fashion. In fact,
the decline of ovarian function during menopause is associated with
an increase in pro-inﬂammatory markers like interleukin (IL)-1, IL-6,
and tumor necrosis factor (TNF)-α [107]. In mouse liver, ERα directly
modulates IL-1β expression [108] and human hepatocytes may
be concerned directly, since ER-expressing HEPG2 cells express less
IL-1β when stimulated by estrogens [109]. The weaker inﬂammatory
response in the liver of females might explain, at least in part, why
they are less susceptible to the progression of liver diseases. In fact,
chronic liver inﬂammation, which reﬂects liver infection (see Section
3.1.2) or a metabolic disturbance (i.e., lipid peroxidation during
steatosis, see Section 4.3), predisposes the liver to cancer.
4.5. Liver cancer
The prevalence of hepatocellular carcinoma (HCC) is higher inmen
than in women [110]; this indicates that male liver cells are more
prone to entering a proliferative state. For instance, hepatic epithelial
growth factor receptor (EGFR), which is overexpressed in a signiﬁcant
proportion of hepatocellular carcinomas, is expressed at higher levels
inmale liver than female liver.Moreover, EGFR expression is enhanced
by AR activation [111]. Collectively, the observations indicate that ER
activation reduces inﬂammation in females and AR activity sustains
infections and steatosis in males. This underscores the necessity of a
balanced, ﬁne-tuned network of NR actions, including those mediated
by PPARs. Therefore, it seems likely that a combination of NR actions
will be important for tumor suppression. In fact, sex-selective in-
duction of hepatic tumors might be a characteristic of different toxic
assaults that can disrupt sexually dimorphic gene expression. This
would have pleiotropic implications for hepatic enzyme activity, lipid
processing, apoptosis, and proliferation [112]. NRs are implicated in
all these processes. Furthermore, NR targeting of miRNA expression
would most likely be involved. In female HCC samples, miR-18a
expressionwas signiﬁcantly enhanced; one of the targets ofmiR-18a is
the UTR region of ERα mRNA. In fact, overexpression of miR18a in
cultures hepatoma cells decreased ERα protein levels and stimulated
their proliferation; this supports the protective role that ERα plays in
liver cell proliferation [113].
5. Sexual dimorphism in NR networks?
Collectively, these observations suggest that male sensitivity to
liver disease is based on an imbalance in the NR signaling network,
rather than a defect in a single NR function. Thus, theNR “interactome”
in males is less stable and more prone to perturbations than that
in females, which results in higher susceptibility to liver steatosis
and cancer. It remains unknown to what extent NR–NR crosstalk is
sex-dimorphic. As proof of concept, we will discuss the evidence forsex-dimorphic crosstalk between two NRs, and we argue that it may
protect women against liver diseases, like intrahepatic cholestasis.
5.1. Sex-dimorphic crosstalk between ER and PPAR
In mice, uterine weight is measured in a classic bio-assay that tests
the female response to estrogenic compounds. One study showed
that treatment with the PPARα ligand, fenoﬁbrate, slightly inhibited
the effect of estrogen on increasing uterine weight; this suggested
that PPAR activation could repress ER signaling in the uterus [114].
Another study showed that estrogen inhibited the action of PPARα on
obesity and lipid metabolism by regulating PPARα-dependent target
genes [115]. Fenoﬁbrate treatment decreased body weight gain and
white adipose tissue (WAT) mass in ovariectomized, but not in sham-
operated female mice [116]. Our group explored a possible molecular
basis for this crosstalk and found that the PPAR/RXR heterodimer
could bind the vitellogenin A2 estrogen response element (ERE)
without activating transcription. Thus, PPAR may antagonize ER
transactivation through competition for ERE binding [117]. It remains
to be determined whether PPARα inhibits ER actions in the liver. This
hypothesis was supported by our previous microarray analysis, which
disclosed a broad, female-speciﬁc, repressive action of PPARα. One of
the genes most repressed by PPARα in female mouse liver encodes
Cyp7b1 [16]. In fact, the male liver contains more Cyp7b1 protein than
the female liver; but, in the PPARα-null female liver, cyp7b1 expression
increased to levels similar to those observed in the male. Cyp7b1
promotes ER activity by catalyzing the clearance of 27-hydroxycholes-
terol, which acts as a competitive ER antagonist [118,119]. In a feed-
forward loop, activated ER indirectly stimulates the expression of
cyp7b1. By a secondmechanism, Cyp7b1 reduces hepatic production of
testosterone by hydroxylating DHEA [120]. Therefore, Cyp7b1 increases
the estrogen/testosterone ratio. Thus, a PPARα-dependent down-
regulation of Cyp7b1 in the female liver could be helpful in protecting
against excess estrogen action. Women who use estrogen-containing
oral contraceptives or postmenopausal hormone replacement therapy
maybe susceptible to estrogen-inducedhepatotoxicity [121].Moreover,
high levels of estrogens cause intrahepatic cholestasis, the most
common hepatic disease that arises during pregnancy. This condition
can result in intrauterine fetal death or spontaneous premature
delivery [122]. We observed that pretreatment of female mice with
ﬁbrate conferred protection against experimental estrogen-induced
intrahepatic cholestasis and inﬂammation. This effect was negligible in
PPARα-null females [16]. In short, PPARα counteracted the negative
effects of estrogen signaling in female liver; this conﬁrmed that NR–NR
crosstalk can be sex-dimorphic.
6. Conclusion
The presently available data indicate that sexual dimorphism is a
major physiological characteristic of the liver, and it has evolved to best
serve the needs of both sexes. An important observation is that female
livers appear to be more resilient than male livers to different
pathologies. In fact, we speculate that the balance of interdependent
systems appears to be less stable in male compared to female liver, and
this results in more vulnerability to diverse derangements (Fig. 3). NRs
play a crucial role in the ﬁne-tuning of gender-speciﬁc metabolic
pathways, including liver functions associated with health and disease.
Further studies on the impact of NRs on sex-dimorphic genes and
on gender-identifying differences are necessary for enhancing our
understanding of the intricate functions of the liver and its roles in
the health of women and men. A comprehensive characterization of
NR-controlled, sex-dimorphic pathways and other factors that deter-
mine liver maintenance and disruption in males and females might
be pivotal in preventive medicine and in the design of safer gender-
speciﬁc therapeutic approaches.
MALE LIVER
LIVER DISEASE
inflammation
lipid accumulation
infection
detoxification
AR
FEMALE LIVER
LIVER DISEASE
inflammation
infection
detoxification
ERPXRCAR
PPARGRGRPXR
CAR
lipid accumulation
Fig. 3. Nuclear receptor sex-dimorphic actions contribute to female resiliency to liver disease. This summary diagram shows the sex differences in nuclear receptor actions, as
discussed in the text. The stimulatory (arrows) and inhibitory (blunt ends) signaling (dashed line=weak, heavy line=strong interaction) empirically supports the hypothesis that
the female liver is more resilient to diseases due to a more robust nuclear receptor network than that in the male liver.
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